Intellectual property is at the forefront of innovation, which means that IP disputes often involve cutting-edge legal developments. Our litigators are experienced in dealing with novel and complex legal issues, and have acted in leading cases which have shaped IP law in their jurisdictions. We handle disputes in all forms...

In life sciences, we have a strong track record in domestic and cross-border mergers and acquisitions, helping our clients to monetise their assets through creative partnering with early-stage entrepreneurial and established companies, and by providing IP and tax advice.

Most law firms look at e-mobility through a single lens. We recognise that understanding this industry requires a real knowledge of how areas such as mobility, energy and digital infrastructure, power management systems, software, data and payments solutions interact – and we're experts in all these.

Contracts are a major factor in business profitability. Our experience, commercial focus and sector knowledge mean that we produce contracts that add the maximum value to your business. That includes expanding sales networks through international agency and distribution networks, outsourcing of non-core operations, procurement of goods and services, joint ventures...

Over the years, our brand has become synonymous with the world of IT and data, with a range of services designed to keep pace with an industry almost entirely defined by innovation and change. Our deep sector knowledge comes from acting for an impressive client base comprising the great and...

The European Commission's report this September on the future of European competitiveness provides critical insights into the economic, regulatory, and technological challenges facing various industries, including the medical device and in vitro diagnostic (IVD) sectors. The report, undertaken by Mario Draghi for the Commission, highlights how medtech companies must navigate...

The European Commission's comprehensive report on the future of European competitiveness has identified critical challenges facing the pharmaceuticals industry as well as among a range of other sectors across Europe. The report, which has been presented by Mario Draghi, the former president of the European Central Bank President and ex-prime...

Poly- and perfluoroalkyl substances (PFAS) are present in most supply chains and consumer products. As the regulatory landscape surrounding these chemicals evolves, it is crucial for businesses to start taking action to future-proof their business. Benefits and concerns PFAS are a class of over 10,000 chemicals known for their beneficial...